Meet team Cerba Research at the Immunogenicity and Bioassay Summit in Washington DC from October 15-18.
Resolve the challenges of immunogenicity testing and risk assessment during preclinical and clinical development, bioassay design & analysis, and how to manipulate the immune system for therapeutic advantage by attending CHI’s 16th Annual Immunogenicity & Bioassay Summit.
Engage with our team of experts to discuss the latest scientific, regulatory, and innovative insights on:
• Bioanalytical assay development/validation services for large molecules, biologics and biosimilars
• Supporting services, including global central laboratory and logistics capabilities
• …. and more
Make sure to attend our speaking slot: Tailoring ADA and NAb assays to different drug modalities:Insights from case studies
Abstract: The presentation will focus on key analytical parameters when setting up ADA and NAb assays specifically dependent on the type of drug product administered to patients. An overview of various approaches for ADA and NAb assays will be provided. Two case studies will highlight issues encountered when in the presence of pre-existing Ab, high signals causing hook effect and matrix effect. Approaches taken to resolve these challenges will be presented.
Meet us at booth nr.12 or click HERE to learn more about our bioanalysis services.
Meet the speaker
Martin Roberge
PhD, Associate Director
Martin Roberge, Ph.D., Associate Director, Bioanalytical Center of Excellence at Cerba Research, has over 26 years of experience in the Life Science industry. Throughout his career in Biotech and Contract Research Organizations, Martin developed a thorough expertise in protein engineering, bioanalysis, and drug development. At Cerba Research, Martin provides leadership and scientific expertise for method development and GLP validation projects for large molecule drug products in support of preclinical and clinical studies. Methods include immunogenicity assays (ADA, NAb), PK assays, biomarkers, qPCR and others.
Cerba Research is a leading specialty laboratory services provider across all clinical development phases, to pharmaceutical, biotechnology, medical device, government, and public health organizations. It combines the deep scientific expertise of specialist services with the capacity and breadth of a global central laboratory network. Cerba Research develops innovative solutions to unique challenges in research and drives operational agility at scale for multiple therapeutic areas, with world recognized expertise in virology, oncology and cell & gene therapy. It is part of the Cerba HealthCare Group with 15,000 employees on five continents, driven to advance health diagnosis.
